Droia Ventures

Hillstar Bio is a biopharmaceutical company focused on developing precision immunotherapies for treating autoimmune diseases. Its innovative approach selectively targets and depletes harmful immune cells, sparing healthy ones, to address specific disease mechanisms and reduce the risks associated with chronic broad immunosuppression. The company aims to provide durable relief and immune reset for patients with autoimmune conditions, addressing unmet medical needs.

Alesta Therapeutics is a biotechnology company focused on developing cancer therapies by targeting stress response pathways and metabolic dependencies that sustain cancer cell survival. It develops small molecule programs to address novel targets within chronic stress responses and synthetic lethal metabolic dependencies in cancer, with the aim of shutting down survival pathways that cancer cells rely on for growth.

Judo Bio is a biotechnology company developing precision therapeutics that target specific cell populations to address genetic diseases. Its innovative receptor targeting approach aims to benefit patients with both common and rare diseases.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Accent Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for oncology, utilizing the emerging field of epitranscriptomics. Founded in 2017 and headquartered in Lexington, Massachusetts, the company explores the post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting cancer-associated RNA-modifying proteins, Accent Therapeutics aims to innovate and deliver transformative therapies that can significantly improve patient outcomes in cancer treatment.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Hyku is a biotechnology company specializing in the development of precise covalent targeting of disease-causing proteins. Its platform identifies molecules that covalently bind non-cysteine amino acids, enabling the creation of innovative medicines designed to address challenges such as selectivity, druggability, and resistance across various diseases.

Actio Biosciences specializes in developing precision medicines tailored to homogeneous rare patient populations. Its pipeline focuses on creating new drugs designed to enhance clinical success rates and ultimately deliver treatments to all patients in need, including those with challenging-to-cure illnesses.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.

Ambagon Therapeutics is a biotechnology company focused on developing small-molecule therapeutics for cancer treatment. The company specializes in research aimed at stabilizing the interactions of oncogenic proteins, which are often difficult to modulate with traditional methods. By selectively enhancing the activity of tumor-suppressing proteins associated with transcription factors and oncoproteins, Ambagon aims to provide new therapeutic options for addressing significant unmet clinical needs in oncology. Founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin, the company is dedicated to advancing innovative solutions in cancer care.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Accent Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for oncology, utilizing the emerging field of epitranscriptomics. Founded in 2017 and headquartered in Lexington, Massachusetts, the company explores the post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting cancer-associated RNA-modifying proteins, Accent Therapeutics aims to innovate and deliver transformative therapies that can significantly improve patient outcomes in cancer treatment.

Montis Biosciences is a biotechnology company founded in 2020 and based in Meise, Belgium. The company focuses on developing innovative immune-oncology therapeutics that address the intersection of vascular dysfunction and immune suppression in the treatment of solid tumors. Montis Biosciences has created a proprietary target screening and assay platform aimed at modulating the interactions between tumor endothelial cells and perivascular macrophages. This research provides valuable insights into the cellular dynamics of these interactions, enabling the development of novel therapeutic strategies to enhance immune responses against various tumors.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment. The company specializes in neoantigen-specific adoptive T-cell therapies aimed at solid tumors. Its innovative platform utilizes bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying candidate neoantigen peptides that stimulate robust antitumor T-cell responses. By pinpointing neo-epitopes unique to each patient's cancer, PACT Pharma enables the engineering of autologous T cells that specifically target and eradicate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is dedicated to advancing personalized medicine in oncology.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Convert Pharmaceuticals SA is a biotech company based in Saint-Gilles, Belgium, founded in 2017. The company focuses on the development of hypoxia-activated cytotoxic small molecules aimed at treating cancer. As a clinical stage enterprise, Convert Pharmaceuticals is building a proprietary drug pipeline that leverages specific factors within the tumor microenvironment to enhance therapeutic outcomes. Its lead product is a hypoxia-activated prodrug designed to overcome the therapeutic challenges posed by hypoxia, which can lead to resistance against conventional cancer treatments. By integrating proprietary insights into the tumor microenvironment with expertise in drug and biomarker development, Convert Pharmaceuticals aims to create effective and well-tolerated therapies for cancer patients.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Founded in 2016, OCTIMET Oncology is a Belgian company dedicated to developing MET kinase inhibitors for cancer treatment. Its strategy involves innovative patient selection and pharmacodynamic biomarker-based approaches.

Cristal Therapeutics BV, established in 2011 and headquartered in Maastricht, the Netherlands, operates as a clinical-stage pharmaceutical company specializing in nanomedicine development. The company's core business revolves around its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted delivery. Cristal Therapeutics focuses on treating diseases such as cancer by improving drug efficacy and safety profiles through this innovative technology.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

NormOxys, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of small molecule drugs for oncology treatment. Founded in 2003 and originally named Oxyplus, Inc., the company changed its name to NormOxys, Inc. in October 2008. It is known for its proprietary product, OXY111A, an effective anti-cancer drug that acts as a novel allosteric modulator, regulating the binding affinity between oxygen and hemoglobin. This mechanism enhances the body’s ability to deliver oxygen to diseased tissues, thereby providing patients with non-toxic therapeutic options.